Scribe Therapeutics Inc.

Scribe Therapeutics Inc.

SCTX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$228.57M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Scribe Therapeutics Inc.Scribe Therapeutics Inc.-2.1---0.2
$51.75

Target Price by Analysts

328.7% upsideScribe Therapeutics Target Price DetailsTarget Price

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$228.57 Million
Enterprise Value$87.08 Million
Earnings per Share$-1.24
Beta0
Outstanding Shares18,936,886

Return

Return on EquityNaN%ROE
Return on AssetsNaN%
Return on Invested CapitalNaN%

Valuation & Multiples

P/E Ratio-2.06P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio2.01Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise0.35
Debt to Equity0.24Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS
-$0.68
Est. -$0.85
Revenue
$1.64 M
Est. $3.72 M

Next Earnings Call

Expected Date
March 3, 2027
EPS Estimate
-$0.65
Consensus analyst estimate
Revenue Estimate
$5.24 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %17.42%▲ 17.42%
Total Invested$60.71M
Investors Holding6▲ 6.00%

About Scribe Therapeutics Inc.

89 employees
CEO: Benjamin L. Oakes

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on...

Scribe Therapeutics Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in Scribe Therapeutics. Notable holders include ARK Invest. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 3 top investors increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 7 open-market insider purchases for Scribe Therapeutics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.